6 reasons to choose indapamide in the treatment of hypertension Review article
Article Sidebar
Published:
Jun 30, 2015
Keywords:
indapamide, sustained release form, diuretics, hypertension
Main Article Content
Abstract
Effective treatment of hypertension due to the spread of the disease in the population is the main target and therapeutic challenge at the same time. Indapamide is one of the main therapeutic options both alone and in combination with other antihypertensive medications with ACE inhibitors in particular. Due to the complex mechanism of action, indapamide effectively reduces blood pressure and also is a drug with very good tolerability and safety of use in different clinical situations also in older patients and with multiple comorbidities which has been confirmed in numerous clinical trials.
Article Details
How to Cite
Domańska , M., & Grzywanowska-Łaniewska, I. (2015). 6 reasons to choose indapamide in the treatment of hypertension. Medycyna Faktow (J EBM), 8(2(27), 39-44. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2309
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Mancia G., Fagard R., Narkiewicz K. et al.: 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). European Heart Journal 2013; 34: 2159-2219.
2. Bansal S., Chauhan D.K., Ramesh D. et al.: Blood pressure control and acceptability of perindopril and its fixed dose combinations with amlodipine or indapamide, in younger patients with hypertension. Indian Heart Journal 2014; 66(6): 635-639.
3. Beckett N.S., Peters R., Fletcher A.E. et al.; HYVET Study Group: Treatment of hypertension in patients 80 years of age or older. N. Engl. J. Med. 2008; 358(18): 1887-1898.
4. Warwick J., Falaschetti E., Rockwood K. et al.: No evidence that frailty modifies the positive impact of antihypertensive treatment in very elderly people: an investigation of the impact of frailty upon treatment effect in the Hypertension in the Very Elderly Trial (HYVET) study, a double-blind, placebo-controlled study of antihypertensives in people with hypertension aged 80 and over. BMC Med. 2015; 13: 78.
5. Piotrowski W., Włodarczyk P., Jasiński B. et al.: Ocena skuteczności i tolerancji indapamidu o powolnym uwalnianiu w dawce 1,5 mg u chorych powyżej 55. r.ż. z izolowanym nadciśnieniem skurczowym. Badanie STIP – 12-tygodniowe otwarte badanie wieloośrodkowe. Nadciśnienie Tętnicze 2001; 5(4): 245-254.
6. Głuszek J., Tykarski A., Duda R. et al.: Ocena skuteczności i tolerancji indapamidu o powolnym uwalnianiu (Tertensif SR) u chorych z nadciśnieniem tętniczym łagodnym i umiarkowanym. Nadciśnienie Tętnicze 2004; 5(8): 327-337.
7. London G., Schmieder R., Calvo C.: Applanation tonometry: artery mechanical properties of indapamide SR vs candesartan and amlodipine: the X-CELLENT tonometry study. J. Hypertens. 2004; 22(supl. 2): S116.
8. Patel A.; ADVANCE Collaborative Group. MacMahon S., Chalmers J., Neal B. et al.: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370(9590): 829-840.
9. Mogensen C.E., Viberti G., Halimi S. et al.; Preterax in Albuminuria Regression (PREMIER) Study Group: Effect of low-dose perindopril/indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIER. Hypertension 2003; 41(5): 1063-1071.
10. Vinereanu D., Dulgheru R., Magda S. et al.: The effect of indapamide versus hydrochlorothiazide on ventricular and arterial function in patients with hypertension and diabetes: results of a randomized trial. Am. Heart J. 2014; 168(4): 446-456.
11. Marre M., Puig J.G., Kokot F. et al.: Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study. J. Hypertens. 2004; 22(8): 1613-1622.
12. PATS Collaborating Group: Post-stroke antihypertensive treatment study. A preliminary result. Chin. Med. J. 1995; 108(9): 710-717.
13. PROGRESS Collaborative Group: Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358(9287): 1033-1041.
14. Gosse P., Sheridan D.J., Zannad F. et al. (on behalf of the LIVE investigators): Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study. J. Hypertens. 2000; 18(10): 1465-1475.
15. Böcker W., Hupf H., Grimm D. et al.: Effects of indapamide in rats with pressure overload left ventricular hypertrophy. J. Cardiovasc. Pharmacol. 2000; 36(4): 481-486.
16. Damien G., de Barochez B.H., Schiavi P.: Galenic development and pharmacokinetic profile of indapamide sustained release 1,5 mg. Clin. Pharmacokinet. 1999; 37(supl. 1): 13-19.
17. Mironneau J.: Indapamide-induced inhibition of calcium movement in smooth muscles. Am. J. Med. 1988; 29(84, 1B): 10-14.
18. Grose J.H., Gbeassor F.M., Lebel M.: Differential effects of diuretics on eicosanoid biosynthesis. Prostaglandins Leukot. Med. 1986; 24(2-3): 103-109.
19. Grimm M., Weidmann P., Meier A. et al.: Correction of altered noradrenaline reactivity in essential hypertension by indapamide. Br. Heart J. 1981; 46(4): 404-409.
20. Finch I., Hicks P.E., Moore R.A.: Changes in vascular reactivity in experimental hypertensive animals following treatment with indapamide. J. Pharm. Pharmacol. 1977; 29: 739-743.
21. Tamura A., Sato T., Fugii T.: Quenching action of oxygen radical by indapamide and its metabolites. J. Med. Pharm. Sci. 1987; 18: 1469.
22. Schini V.B., Dewey J., Vanhoutte P.M.: Effects of indapamide on endothelium-dependent relaxations in isolated canine femoral arteries. Am. J. Cardiol. 1990; 65(17): 6H-10H.
23. Carretta R., Fabris B., Tonutti L. et al.: Effect of indapamide on the baroreceptor reflex in essential hypertension. Eur. J. Clin. Pharmacol. 1983; 24(5): 579-583.
24. Harrower A.D., McFarlane G.: Antihypertensive therapy in diabetic patients. The use of indapamide. Am. J. Med. 1988; 84(1B): 89-91.
25. Osei K., Holland G., Falko J.M.: Indapamide. Effects on apoprotein, lipoprotein, and glucoregulation in ambulatory diabetic patients. Arch. Intern. Med. 1986; 146(10): 1973-1977.
26. Meyer-Sabellek W., Gotzen R., Heitz J. et al.: Serum lipoprotein levels during long-term treatment of hypertension with indapamide. Hypertension 1985; 7(6 Pt 2): II 170-174.
27. Kasiske B.L., Ma J.Z., Kalil R.S.N. et al.: Effects of antihypertensive therapy on serum lipids. Ann. Intern. Med. 1995; 122: 133-141.
28. Ames R.P., Kuritsky L.: Indapamide does it differ from low-dose thiazides? W: Cardiovascular drug therapy. Messerli E.H. (red.). Saunders 1996: 432-434.
29. Uruski P., Tykarski A.: Miejsce indapamidu o przedłużonym uwalnianiu w terapii nadciśnienia tętniczego. Nadciśnienie Tętnicze 2009; 13(supl. B): B1-B24.
2. Bansal S., Chauhan D.K., Ramesh D. et al.: Blood pressure control and acceptability of perindopril and its fixed dose combinations with amlodipine or indapamide, in younger patients with hypertension. Indian Heart Journal 2014; 66(6): 635-639.
3. Beckett N.S., Peters R., Fletcher A.E. et al.; HYVET Study Group: Treatment of hypertension in patients 80 years of age or older. N. Engl. J. Med. 2008; 358(18): 1887-1898.
4. Warwick J., Falaschetti E., Rockwood K. et al.: No evidence that frailty modifies the positive impact of antihypertensive treatment in very elderly people: an investigation of the impact of frailty upon treatment effect in the Hypertension in the Very Elderly Trial (HYVET) study, a double-blind, placebo-controlled study of antihypertensives in people with hypertension aged 80 and over. BMC Med. 2015; 13: 78.
5. Piotrowski W., Włodarczyk P., Jasiński B. et al.: Ocena skuteczności i tolerancji indapamidu o powolnym uwalnianiu w dawce 1,5 mg u chorych powyżej 55. r.ż. z izolowanym nadciśnieniem skurczowym. Badanie STIP – 12-tygodniowe otwarte badanie wieloośrodkowe. Nadciśnienie Tętnicze 2001; 5(4): 245-254.
6. Głuszek J., Tykarski A., Duda R. et al.: Ocena skuteczności i tolerancji indapamidu o powolnym uwalnianiu (Tertensif SR) u chorych z nadciśnieniem tętniczym łagodnym i umiarkowanym. Nadciśnienie Tętnicze 2004; 5(8): 327-337.
7. London G., Schmieder R., Calvo C.: Applanation tonometry: artery mechanical properties of indapamide SR vs candesartan and amlodipine: the X-CELLENT tonometry study. J. Hypertens. 2004; 22(supl. 2): S116.
8. Patel A.; ADVANCE Collaborative Group. MacMahon S., Chalmers J., Neal B. et al.: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370(9590): 829-840.
9. Mogensen C.E., Viberti G., Halimi S. et al.; Preterax in Albuminuria Regression (PREMIER) Study Group: Effect of low-dose perindopril/indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIER. Hypertension 2003; 41(5): 1063-1071.
10. Vinereanu D., Dulgheru R., Magda S. et al.: The effect of indapamide versus hydrochlorothiazide on ventricular and arterial function in patients with hypertension and diabetes: results of a randomized trial. Am. Heart J. 2014; 168(4): 446-456.
11. Marre M., Puig J.G., Kokot F. et al.: Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study. J. Hypertens. 2004; 22(8): 1613-1622.
12. PATS Collaborating Group: Post-stroke antihypertensive treatment study. A preliminary result. Chin. Med. J. 1995; 108(9): 710-717.
13. PROGRESS Collaborative Group: Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358(9287): 1033-1041.
14. Gosse P., Sheridan D.J., Zannad F. et al. (on behalf of the LIVE investigators): Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study. J. Hypertens. 2000; 18(10): 1465-1475.
15. Böcker W., Hupf H., Grimm D. et al.: Effects of indapamide in rats with pressure overload left ventricular hypertrophy. J. Cardiovasc. Pharmacol. 2000; 36(4): 481-486.
16. Damien G., de Barochez B.H., Schiavi P.: Galenic development and pharmacokinetic profile of indapamide sustained release 1,5 mg. Clin. Pharmacokinet. 1999; 37(supl. 1): 13-19.
17. Mironneau J.: Indapamide-induced inhibition of calcium movement in smooth muscles. Am. J. Med. 1988; 29(84, 1B): 10-14.
18. Grose J.H., Gbeassor F.M., Lebel M.: Differential effects of diuretics on eicosanoid biosynthesis. Prostaglandins Leukot. Med. 1986; 24(2-3): 103-109.
19. Grimm M., Weidmann P., Meier A. et al.: Correction of altered noradrenaline reactivity in essential hypertension by indapamide. Br. Heart J. 1981; 46(4): 404-409.
20. Finch I., Hicks P.E., Moore R.A.: Changes in vascular reactivity in experimental hypertensive animals following treatment with indapamide. J. Pharm. Pharmacol. 1977; 29: 739-743.
21. Tamura A., Sato T., Fugii T.: Quenching action of oxygen radical by indapamide and its metabolites. J. Med. Pharm. Sci. 1987; 18: 1469.
22. Schini V.B., Dewey J., Vanhoutte P.M.: Effects of indapamide on endothelium-dependent relaxations in isolated canine femoral arteries. Am. J. Cardiol. 1990; 65(17): 6H-10H.
23. Carretta R., Fabris B., Tonutti L. et al.: Effect of indapamide on the baroreceptor reflex in essential hypertension. Eur. J. Clin. Pharmacol. 1983; 24(5): 579-583.
24. Harrower A.D., McFarlane G.: Antihypertensive therapy in diabetic patients. The use of indapamide. Am. J. Med. 1988; 84(1B): 89-91.
25. Osei K., Holland G., Falko J.M.: Indapamide. Effects on apoprotein, lipoprotein, and glucoregulation in ambulatory diabetic patients. Arch. Intern. Med. 1986; 146(10): 1973-1977.
26. Meyer-Sabellek W., Gotzen R., Heitz J. et al.: Serum lipoprotein levels during long-term treatment of hypertension with indapamide. Hypertension 1985; 7(6 Pt 2): II 170-174.
27. Kasiske B.L., Ma J.Z., Kalil R.S.N. et al.: Effects of antihypertensive therapy on serum lipids. Ann. Intern. Med. 1995; 122: 133-141.
28. Ames R.P., Kuritsky L.: Indapamide does it differ from low-dose thiazides? W: Cardiovascular drug therapy. Messerli E.H. (red.). Saunders 1996: 432-434.
29. Uruski P., Tykarski A.: Miejsce indapamidu o przedłużonym uwalnianiu w terapii nadciśnienia tętniczego. Nadciśnienie Tętnicze 2009; 13(supl. B): B1-B24.